Skip to main content

Articles

Page 2 of 64

  1. Tumor immunotherapy has transformed neoplastic disease management, yet low response rates and immune complications persist as major challenges. Extracellular vesicles including exosomes have emerged as therape...

    Authors: Ming Yue, Shengyun Hu, Haifeng Sun, Baojing Tuo, Bin Jia, Chen Chen, Wenkang Wang, Jinbo Liu, Yang Liu, Zhenqiang Sun and Junhong Hu
    Citation: Molecular Cancer 2023 22:203
  2. Autophagy is an essential cellular homeostasis pathway initiated by multiple stimuli ranging from nutrient deprivation to viral infection, playing a key role in human health and disease. At present, a growing ...

    Authors: Manuela Giansanti, Tobias Theinert, Sarah Katharina Boeing, Dorothee Haas, Paul-Gerhardt Schlegel, Paola Vacca, Francesca Nazio and Ignazio Caruana
    Citation: Molecular Cancer 2023 22:201
  3. Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contri...

    Authors: Yunlin Zhang, Ruchi P. Patel, Ki Hyun Kim, Hyungwoo Cho, Jae-Cheol Jo, Seong Hyun Jeong, Sung Yong Oh, Yoon Seok Choi, Sung Hyun Kim, Ji Hyun Lee, Mathew Angelos, Puneeth Guruprasad, Ivan Cohen, Ositadimma Ugwuanyi, Yong Gu Lee, Raymone Pajarillo…
    Citation: Molecular Cancer 2023 22:200
  4. Colorectal cancer (CRC) is one of the most threatening tumors in the world, and chemotherapy remains dominant in the treatment of metastatic CRC (mCRC) patients. The purpose of this study was to develop a biom...

    Authors: Ya’nan Yang, Jieyun Zhang, Wen Zhang, Yixuan Wang, Yujia Zhai, Yan Li, Wenhua Li, Jinjia Chang, Xiaoying Zhao, Mingzhu Huang, Qirong Geng, Yue Yang, Zhe Gong, Nuoya Yu, Wei Shen, Qian Li…
    Citation: Molecular Cancer 2023 22:199
  5. Tumor angiogenesis plays vital roles in the growth and metastasis of cancer. RNA methylation is one of the most common modifications and is widely observed in eukaryotes and prokaryotes. Accumulating studies h...

    Authors: Mingyu Han, Haifeng Sun, Quanbo Zhou, Jinbo Liu, Junhong Hu, Weitang Yuan and Zhenqiang Sun
    Citation: Molecular Cancer 2023 22:198
  6. Hepatocellular carcinoma (HCC), one of the most prevalent forms of cancer worldwide, presents a significant global healthcare challenge. Cancer stem cells (CSCs), which can influence neighboring non-CSCs, are ...

    Authors: Tao Han, Lujun Chen, Kerui Li, Qilin Hu, Yue Zhang, Xuan You, Lei Han, Tingsong Chen and Kai Li
    Citation: Molecular Cancer 2023 22:197
  7. Pharmacologic targeting of chromatin-associated protein complexes has shown significant responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance frequently develops to single agents. Th...

    Authors: Nuria Tubío-Santamaría, Ashok Kumar Jayavelu, Tina M. Schnoeder, Theresa Eifert, Chen-Jen Hsu, Florian Perner, Qirui Zhang, Daniela V. Wenge, Fynn M. Hansen, Joanna M. Kirkpatrick, Nidhi Jyotsana, Steven W. Lane, Björn von Eyss, Aniruddha J. Deshpande, Michael W. M. Kühn, Juerg Schwaller…
    Citation: Molecular Cancer 2023 22:196
  8. Circular RNAs (circRNAs) play important roles in the occurrence and development of cancer and chemoresistance. DNA damage repair contributes to the proliferation of cancer cells and resistance to chemotherapy-...

    Authors: Lei Xu, Xiao Ma, Xiuzhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo, Mengmeng Zhao, Zeqiang Ren and Pengbo Zhang
    Citation: Molecular Cancer 2023 22:195

    The Correction to this article has been published in Molecular Cancer 2024 23:16

  9. Current research has demonstrated that extracellular vesicles (EVs) and circulating tumor cells (CTCs) are very closely related in the process of distant tumor metastasis. Primary tumors are shed and released ...

    Authors: Siyin Guo, Jing Huang, Genpeng Li, Wenjie Chen, Zhihui Li and Jianyong Lei
    Citation: Molecular Cancer 2023 22:193
  10. Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the...

    Authors: Andrea Sacconi, Paola Muti, Claudio Pulito, Giulia Urbani, Matteo Allegretti, Raul Pellini, Nikolay Mehterov, Uri Ben-David, Sabrina Strano, Paolo Bossi and Giovanni Blandino
    Citation: Molecular Cancer 2023 22:192
  11. Despite major improvements in immunotherapeutic strategies, the immunosuppressive tumor microenvironment remains a major obstacle for the induction of efficient antitumor responses. In this study, we show that...

    Authors: Sandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, Niels Vandamme, Stephane Plaisance, Annick Verhee, Dominiek Catteeuw, Elke Rogge, Jennifer De Geest, Nele Vanderroost, Jana Roels, Yvan Saeys, Gilles Uzé, Niko Kley, Anje Cauwels and Jan Tavernier
    Citation: Molecular Cancer 2023 22:191
  12. Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matr...

    Authors: Pere Llinàs-Arias, Miquel Ensenyat-Mendez, Sandra Íñiguez-Muñoz, Javier I. J. Orozco, Betsy Valdez, Matthew P. Salomon, Chikako Matsuba, Maria Solivellas-Pieras, Andrés F. Bedoya-López, Borja Sesé, Anja Mezger, Mattias Ormestad, Fernando Unzueta, Siri H. Strand, Alexander D. Boiko, E Shelley Hwang…
    Citation: Molecular Cancer 2023 22:190
  13. The advent of iPSCs has brought about a significant transformation in stem cell research, opening up promising avenues for advancing cancer treatment. The formation of cancer is a multifaceted process influenc...

    Authors: Matin Chehelgerdi, Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi, Hamidreza Kabiri, Hosein Salehian-Dehkordi, Mohammad Abdolvand, Sharareh Salmanizadeh, Mohsen Rashidi, Anoosha Niazmand, Saba Ahmadi, Sara Feizbakhshan, Saber Kabiri, Nasimeh Vatandoost and Tayebeh Ranjbarnejad
    Citation: Molecular Cancer 2023 22:189
  14. Immunotherapies have revolutionized the treatment paradigms of various types of cancers. However, most of these immunomodulatory strategies focus on harnessing adaptive immunity, mainly by inhibiting immunosup...

    Authors: Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai and Kongming Wu
    Citation: Molecular Cancer 2023 22:187
  15. Currently, only limited knowledge is available regarding the phenotypic association between fibroblast growth factor receptor 3 (FGFR3) alterations and the tumor microenvironment (TME) in bladder cancer (BLCA).

    Authors: Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Takai…
    Citation: Molecular Cancer 2023 22:185
  16. Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system. Angiogenesis is a main contributing factor for tumorigenesis. E74-like transcription factor 5 (ELF5) has been verified to participa...

    Authors: Tushuai Li, Longjiang Xu, Zhe Wei, Shaomei Zhang, Xingyu Liu, Yanzi Yang, Yue Gu and Jie Zhang
    Citation: Molecular Cancer 2023 22:184
  17. Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors...

    Authors: Faezeh Ramezani, Ahmad Reza Panahi Meymandi, Behnia Akbari, Omid Reza Tamtaji, Hamed Mirzaei, Christine E. Brown and Hamid Reza Mirzaei
    Citation: Molecular Cancer 2023 22:183
  18. Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivoluma...

    Authors: Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu…
    Citation: Molecular Cancer 2023 22:182
  19. The limited sensitivity of circulating tumor cell (CTC) detection in pancreatic adenocarcinoma (PDAC) stems from their extremely low concentration in the whole circulating blood, necessitating enhanced detecti...

    Authors: Nikolas H. Stoecklein, Georg Fluegen, Rosa Guglielmi, Rui P.L. Neves, Thilo Hackert, Emrullah Birgin, Stefan A. Cieslik, Monica Sudarsanam, Christiane Driemel, Guus van Dalum, André Franken, Dieter Niederacher, Hans Neubauer, Tanja Fehm, Jutta M. Rox, Petra Böhme…
    Citation: Molecular Cancer 2023 22:181
  20. Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the expansion of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in failure of normal hematopoiesis a...

    Authors: Tatjana Sauerer, Giuliano Filippini Velázquez and Christoph Schmid
    Citation: Molecular Cancer 2023 22:180
  21. Noncoding RNAs such as circular RNAs (circRNAs) are abundant in the human body and influence the occurrence and development of various diseases. Non-small cell lung cancer (NSCLC) is one of the most common mal...

    Authors: Yumeng Cui, Xiaojie Wu, Jie Jin, Weiling Man, Jie Li, Xiang Li, Yanghua Li, He Yao, Rongbin Zhong, Shiyun Chen, Jiahui Wu, Tianhao Zhu, Yanli Lin, Junjie Xu and Youliang Wang
    Citation: Molecular Cancer 2023 22:179
  22. Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instabi...

    Authors: Cyril Roussel-Simonin, Felix Blanc-Durand, Roseline Tang, Damien Vasseur, Audrey Le Formal, Laure Chardin, Elisa Yaniz, Sébastien Gouy, Amandine Maulard, Stéphanie Scherier, Claire Sanson, Ludovic Lacroix, Sophie Cotteret, Lea Mauny, François Zaccarini, Etienne Rouleau…
    Citation: Molecular Cancer 2023 22:178
  23. Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remain...

    Authors: Ji Eun Shin, Soo-Hyun Kim, Mingyu Kong, Hwa-Ryeon Kim, Sungmin Yoon, Kyung-Mi Kee, Jung Ah Kim, Dong Hyeon Kim, So Yeon Park, Jae Hyung Park, Hongtae Kim, Kyoung Tai No, Han-Woong Lee, Heon Yung Gee, Seunghee Hong, Kun-Liang Guan…
    Citation: Molecular Cancer 2023 22:177
  24. Despite the effectiveness of the various targeted therapies currently approved for solid tumors, acquired resistance remains a persistent problem that limits the ultimate effectiveness of these treatments. Pol...

    Authors: Arnaud Bayle, Laila Belcaid, Lola-Jade Palmieri, Diego Teysonneau, Sophie Cousin, Mariella Spalato-Ceruso, Mihaela Aldea, Damien Vasseur, Melissa Alame, Laura Blouin, Isabelle Soubeyran, Claudio Nicotra, Maud Ngocamus, Antoine Hollebecque, Yohann Loriot, Benjamin Besse…
    Citation: Molecular Cancer 2023 22:176
  25. Vascular invasion is a major route for intrahepatic and distant metastasis in hepatocellular carcinoma (HCC) and is a strong negative prognostic factor. Circular RNAs (circRNAs) play important roles in tumorig...

    Authors: Liangliang Xu, Peng Wang, Li Li, Lian Li, Yang Huang, Yanfang Zhang, Xiaobo Zheng, Pengsheng Yi, Ming Zhang and Mingqing Xu
    Citation: Molecular Cancer 2023 22:174
  26. Authors: Tao Xie, Du-jiang Fu, Zhi-min Li, Dao-jun Lv, Xian-Lu Song, Yu-zhong Yu, Chong Wang, Kang-jin Li, Baoqian Zhai, Jiacheng Wu, Ning-Han Feng and Shan-Chao Zhao
    Citation: Molecular Cancer 2023 22:173

    The original article was published in Molecular Cancer 2022 21:173

  27. Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their behavior is regulated throu...

    Authors: Zhen Zeng, Minyang Fu, Yuan Hu, Yuquan Wei, Xiawei Wei and Min Luo
    Citation: Molecular Cancer 2023 22:172
  28. Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population that plays a crucial role in remodeling the tumor microenvironment (TME). Here, through the integrated analysis of spatial and single-ce...

    Authors: Chenxi Ma, Chengzhe Yang, Ai Peng, Tianyong Sun, Xiaoli Ji, Jun Mi, Li Wei, Song Shen and Qiang Feng
    Citation: Molecular Cancer 2023 22:170
  29. The use of nanotechnology has the potential to revolutionize the detection and treatment of cancer. Developments in protein engineering and materials science have led to the emergence of new nanoscale targetin...

    Authors: Mohammad Chehelgerdi, Matin Chehelgerdi, Omer Qutaiba B. Allela, Renzon Daniel Cosme Pecho, Narayanan Jayasankar, Devendra Pratap Rao, Tamilanban Thamaraikani, Manimaran Vasanthan, Patrik Viktor, Natrayan Lakshmaiya, Mohamed J. Saadh, Ayesha Amajd, Mabrouk A. Abo-Zaid, Roxana Yolanda Castillo-Acobo, Ahmed H. Ismail, Ali H. Amin…
    Citation: Molecular Cancer 2023 22:169
  30. Skin cancer is a global threat to the healthcare system and is estimated to incline tremendously in the next 20 years, if not diagnosed at an early stage. Even though it is curable at an early stage, novel dru...

    Authors: Nazeer Hasan, Arif Nadaf, Mohammad Imran, Umme Jiba, Afsana Sheikh, Waleed H. Almalki, Salem Salman Almujri, Yousuf Hussain Mohammed, Prashant Kesharwani and Farhan Jalees Ahmad
    Citation: Molecular Cancer 2023 22:168
  31. Interferon-gamma (IFNγ) exerts potent growth inhibitory effects on a wide range of cancer cells through unknown signaling pathways. We pursued complementary screening approaches to characterize the growth inhi...

    Authors: Ameya Champhekar, Rachel Heymans, Justin Saco, Guillem Turon Font, Cynthia Gonzalez, Anne Gao, John Pham, June Lee, Ryan Maryoung, Egmidio Medina, Katie M. Campbell, Daniel Karin, David Austin, Robert Damioseaux and Antoni Ribas
    Citation: Molecular Cancer 2023 22:165

    The Correction to this article has been published in Molecular Cancer 2024 23:29

  32. To address the shortcomings of current hepatocellular carcinoma (HCC) surveillance tests, we set out to find HCC-specific methylation markers and develop a highly sensitive polymerase chain reaction (PCR)-base...

    Authors: Si-Cho Kim, Da-Won Kim, Eun Ju Cho, Jin-Young Lee, Jiwon Kim, Chaesun Kwon, Jeongsil Kim-Ha, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Won Kim, Woojin Kim, Hyunsoo Kim, Yoon Jun Kim…
    Citation: Molecular Cancer 2023 22:164
  33. Lysine crotonylation (Kcr) is up-regulation in colorectal cancer (CRC) tissues, while its specific contribution remains uncertain. This study aimed to elucidate the role and mechanism of crotonylation on Lys27...

    Authors: Meijian Liao, Xiaolin Sun, Wendan Zheng, Mengdi Wu, Yifan Wang, Jia Yao, Yu Ma, Shoucui Gao and Dongsheng Pei
    Citation: Molecular Cancer 2023 22:163
  34. Genetic signatures have added a molecular dimension to prognostics and therapeutic decision-making. However, tumour heterogeneity in prostate cancer and current sampling methods could confound accurate assessm...

    Authors: Sandy Figiel, Wencheng Yin, Dimitrios Doultsinos, Andrew Erickson, Ninu Poulose, Reema Singh, Anette Magnussen, Thineskrishna Anbarasan, Renuka Teague, Mengxiao He, Joakim Lundeberg, Massimo Loda, Clare Verrill, Richard Colling, Pelvender S. Gill, Richard J. Bryant…
    Citation: Molecular Cancer 2023 22:162
  35. Fecal microRNAs represent promising molecules with potential clinical interest as non-invasive diagnostic and prognostic biomarkers. Colorectal cancer (CRC) screening based on the fecal immunochemical test (FI...

    Authors: Einar Birkeland, Giulio Ferrero, Barbara Pardini, Sinan U. Umu, Sonia Tarallo, Sara Bulfamante, Geir Hoff, Carlo Senore, Trine B Rounge and Alessio Naccarati
    Citation: Molecular Cancer 2023 22:161
  36. Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug therapy. But presently, detailed investigations have revealed their flaws as drug delivery carriers. Lipid polymer hyb...

    Authors: Kavita R. Gajbhiye, Rajesh Salve, Mahavir Narwade, Afsana Sheikh, Prashant Kesharwani and Virendra Gajbhiye
    Citation: Molecular Cancer 2023 22:160
  37. Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal compone...

    Authors: Hao Zhang, Xinghai Yue, Zhe Chen, Chao Liu, Wantao Wu, Nan Zhang, Zaoqu Liu, Liping Yang, Qing Jiang, Quan Cheng, Peng Luo and Guodong Liu
    Citation: Molecular Cancer 2023 22:159
  38. The Eyes Absent (EYA) family of proteins is an atypical group of four dual-functioning protein phosphatases (PP), which have been linked to many vital cellular processes and organogenesis pathways. The four fa...

    Authors: Bárbara de la Peña Avalos, Romain Tropée, Pascal H. G. Duijf and Eloïse Dray
    Citation: Molecular Cancer 2023 22:158
  39. Although colonoscopy is the standard screening test for colorectal cancer (CRC), its use is limited by a poor compliance rate, the need for extensive bowel preparation, and the risk of complications. As an alt...

    Authors: Fuqiang Zhao, Ping Bai, Jianfeng Xu, Zitong Li, Shan Muhammad, Diange Li, Zeyue Zhang, Yibo Gao and Qian Liu
    Citation: Molecular Cancer 2023 22:157
  40. Targetable molecular drivers of gastric cancer (GC) metastasis remain largely unidentified, leading to limited targeted therapy options for advanced GC. We aimed to identify molecular drivers for metastasis an...

    Authors: Jong-Wan Kwon, Jeong-Seop Oh, Sang Hyeok Seok, Hyeok-Won An, Yu Jin Lee, Na Yun Lee, Taehun Ha, Hyeon Ah Kim, Gyeong Min Yoon, Sung Eun Kim, Pu-Reum Oh, Su-Hyung Lee, Dominic C. Voon, Dae-Yong Kim and Jun Won Park
    Citation: Molecular Cancer 2023 22:156

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2022 Speed
    7 days submission to first editorial decision for all manuscripts (Median)
    76 days submission to accept (Median)

    2022 Usage 
    3,062,329 downloads
    4,920 Altmetric mentions